Compare Heron Therapeutics Inc (HRTX) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Tyson Foods, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Tyson Foods, Inc. trades at $56.65 (market cap $20.11B). The key difference: Tyson Foods, Inc. is far larger — about 317.1× Heron Therapeutics Inc's market cap, and Tyson Foods, Inc. pays a 3.57% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | TSN | |
|---|---|---|
Market Cap | $63.41M | $20.11B |
Sector | Health | Consumer Staples |
52-Week High | $1.49 | $68.75 |
52-Week Low | $0.32 | $50.72 |
Enterprise Value | $161.31M | $27.37B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Tyson Foods (TSN) trades at $58.04, down 0.85% on the day, with a bearish technical signal and mixed earnings history. The company reported Q3 2026 EPS of $0.99, beating estimates, but revenue trends are pressured by beef segment losses. Valuation metrics show a P/E of 35.83 and P/S of 0.37, with a consensus analyst price target of $68.50. Recent news highlights debt tender offers and a maintained quarterly dividend of $0.51.
The outlook is cautious due to persistent beef margin challenges, though chicken and prepared foods provide stability. Investment appeal lies in the discounted valuation and dividend yield, but risks include volatile input costs and competitive pressures. Analyst sentiment is divided, with 50% buy ratings but bearish technical indicators suggesting near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
